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Conclusion
The target compounds, myr-(D-Orn)3-NH2 and its enantiomer

21.6
22.189
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residues were designed and tested [1]. The tripeptide myr-(L-Orn)3-NH2 was found to have
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the best antimicrobial activity. Previous studies have shown that peptides with D-residues
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were more stable than those with L-residues [2]. This project aimed to evaluate the effect of
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purified, characterized and tested for their anti-microbial activities against E. coli and
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S.aureus than E.coli. Although the L-lipopeptide was slightly
more active than the D-lipopeptide, the results verify that these antimicrobial agents kill

compound, myr-(D-Orn)3-NH2 and its enantiomer, myr-(L-Orn)3-NH2, were synthesized,

Methodology

analysis

lipopeptides exhibited better antimicrobial activity against

incorporating D-amino acid residues into a known antimicrobial lipopeptide. The target

S. aureus.

lipopeptide

C29N14O4H60 = 569.46 (calc)

Fig 4. HPLC chromatogram of L (top)
and D- (bottom) lipopeptides after
purification by preparative HPLC

(D-Orn)3-NH2 could prove to be an excellent drug candidate.
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The researchers learned that developing a drug entails a lot of work. It is recommended
that the stability of the L and D lipopeptides be checked. Furthermore, the activity of the
myr-(L-Orn)3-NH2

lipopeptides against more resistant strains of bacteria and its antifungal activity could be
tested. Finally, to test the viability of the lipopeptide as a drug, it is the hemolytic ability of
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Fig 5. Mass spectra of myr-(D-Orn)3-NH2 (top) and myr-(D-Orn)3NH2 (bottom) after purification by reverse phase preparative HPLC
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Fig 6. Circular Dichroism spectra of myr-(L-Orn)3-NH2
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Table 1. MIC values in M of the lipopeptides
and ampicillin against E.coli and S. aureus .
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the two lipopeptides could also be checked.
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